134 related articles for article (PubMed ID: 26418334)
41. Increased survival and decreased recurrence in colorectal cancer patients diagnosed in a screening programme.
Mengual-Ballester M; Pellicer-Franco E; Valero-Navarro G; Soria-Aledo V; García-Marín JA; Aguayo-Albasini JL
Cancer Epidemiol; 2016 Aug; 43():70-5. PubMed ID: 27399311
[TBL] [Abstract][Full Text] [Related]
42. The impact of colorectal cancer screening in a veteran hospital population.
Trombold J; Farmer RW; McCafferty M
Am Surg; 2013 Mar; 79(3):296-300. PubMed ID: 23461957
[TBL] [Abstract][Full Text] [Related]
43. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up.
Scholefield JH; Moss SM; Mangham CM; Whynes DK; Hardcastle JD
Gut; 2012 Jul; 61(7):1036-40. PubMed ID: 22052062
[TBL] [Abstract][Full Text] [Related]
44. Equity of colorectal cancer screening: cross-sectional analysis of National Bowel Cancer Screening Program data for South Australia.
Ward PR; Javanparast S; Matt MA; Martini A; Tsourtos G; Cole S; Gill T; Aylward P; Baratiny G; Jiwa M; Misan G; Wilson C; Young G
Aust N Z J Public Health; 2011 Feb; 35(1):61-5. PubMed ID: 21299702
[TBL] [Abstract][Full Text] [Related]
45. Realized impact of COVID-19 related disruptions on the National Bowel Cancer Screening Program.
Irwin MP; Dutta T; Jambor MA; Morgan MJ; Turner CE; Liang Y
ANZ J Surg; 2024 Feb; ():. PubMed ID: 38345127
[TBL] [Abstract][Full Text] [Related]
46. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test.
Zorzi M; Fedeli U; Schievano E; Bovo E; Guzzinati S; Baracco S; Fedato C; Saugo M; Dei Tos AP
Gut; 2015 May; 64(5):784-90. PubMed ID: 25179811
[TBL] [Abstract][Full Text] [Related]
47. Faecal immunochemical test-based colorectal cancer screening programme SVIT in Slovenia: pilot phase.
Tepeš B; Stabuc B; Stefanovič M; Bračko M; Frkovič Grazio S; Novak Mlakar D; Maučec Zakotnik J
Eur J Cancer Prev; 2014 Jul; 23(4):235-9. PubMed ID: 24030444
[TBL] [Abstract][Full Text] [Related]
48. Improving colonoscopy prioritisation and promoting the National Bowel Cancer Screening Program: keys to reducing bowel cancer burden.
Grogan P; He E; Pockney P
Public Health Res Pract; 2023 Mar; 33(1):. PubMed ID: 36918394
[TBL] [Abstract][Full Text] [Related]
49. Socio-demographic factors drive regional differences in participation in the National Bowel Cancer Screening Program - An ecological analysis.
Sun J; March S; Ireland MJ; Crawford-Williams F; Goodwin B; Hyde MK; Chambers SK; Aitken JF; Dunn J
Aust N Z J Public Health; 2018 Feb; 42(1):92-97. PubMed ID: 29044846
[TBL] [Abstract][Full Text] [Related]
50. Asymptomatic breast cancer in non-participants of the national screening programme in Norway: a confounding factor in evaluation?
Hoff SR; Klepp O; Hofvind S
J Med Screen; 2012 Dec; 19(4):177-83. PubMed ID: 23486698
[TBL] [Abstract][Full Text] [Related]
51. Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching.
Leuraud K; Jezewski-Serra D; Viguier J; Salines E
Cancer Epidemiol; 2013 Dec; 37(6):959-67. PubMed ID: 24035240
[TBL] [Abstract][Full Text] [Related]
52. Impact of the Scottish Bowel Cancer Screening Programme on patient and tumour characteristics at a single centre.
Mackay C; Ramsay G; Rafferty A; Loudon M
J Eval Clin Pract; 2014 Feb; 20(1):7-11. PubMed ID: 23890078
[TBL] [Abstract][Full Text] [Related]
53. The NHS Bowel cancer screening programme achieves the anticipated survival improvement, but participation must be improved.
Borowski DW; Cawkwell S; Zaidi SMA; Toward M; Maguire N; Garg DK; Gill TS
Int J Health Care Qual Assur; 2018 Mar; 31(2):106-115. PubMed ID: 29504872
[TBL] [Abstract][Full Text] [Related]
54. Impact of the bowel-screening programme on the diagnosis of colorectal cancer in Ayrshire and Arran.
Roxburgh CS; McTaggart F; Balsitis M; Diament RH
Colorectal Dis; 2013 Jan; 15(1):34-41. PubMed ID: 22632378
[TBL] [Abstract][Full Text] [Related]
55. [Results of the Czech National Colorectal Cancer screening programme - faecal occult blood tests].
Seifert B; Májek O; Zavoral M; Král N; Suchánek S; Ngo O; Dušek L
Klin Onkol; 2014; 27 Suppl 2():87-97. PubMed ID: 25494893
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program.
Chiu HM; Chen SL; Yen AM; Chiu SY; Fann JC; Lee YC; Pan SL; Wu MS; Liao CS; Chen HH; Koong SL; Chiou ST
Cancer; 2015 Sep; 121(18):3221-9. PubMed ID: 25995082
[TBL] [Abstract][Full Text] [Related]
57. Stage distribution of breast cancer diagnosed before and after implementation of population-based mammographic screening.
Hofvind S; Skaane P
Rofo; 2012 May; 184(5):437-42. PubMed ID: 22426937
[TBL] [Abstract][Full Text] [Related]
58. Impact of the United Kingdom national bowel cancer awareness campaigns 2012 on colorectal cancer services and patient survival.
Khong TL; Naik K; Sivakumar R; Shah S
Colorectal Dis; 2015 Dec; 17(12):1055-61. PubMed ID: 26096269
[TBL] [Abstract][Full Text] [Related]
59. Colorectal cancer screening.
Leggett BA; Hewett DG
Intern Med J; 2015 Jan; 45(1):6-15. PubMed ID: 25582937
[TBL] [Abstract][Full Text] [Related]
60. Relative impact of earlier diagnosis and improved treatment on survival for colorectal cancer: a US database study among elderly.
Tong L; Ahn C; Symanski E; Lai D; Du XL
Cancer Epidemiol; 2014 Dec; 38(6):733-40. PubMed ID: 25454261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
